Discover
PROK
ProKidney Corp.
1.89
2 x 1.45
2 x 2.43
bid
ask
-
0.15
7.35%
2 @ 04:01 AM
1.90 +0.01 (0.53%)
| Ytd | -15.63% | |
| 1y | 234.51% |
1.87
day range
2.04
0.55
52 week range
7.13
| Open | 2.02 | Prev Close | 2.04 | Low | 1.87 | High | 2.04 | Mkt Cap | 570.89M |
| Vol | 1.38M | Avg Vol | 1.12M | EPS | -0.53 | P/E | N/A | Forward P/E | -5.33 |
| Beta | 1.79 | Short Ratio | 3.72 | Inst. Own | 30.44% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 1.81 | 200-d Avg | 2.22 | 1yr Est | 5.83 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-11-11 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-08-12 | 2025-06 | 0 | N/A | 0.01 | 7.14% |
| 2025-05-12 | 2025-03 | 0 | N/A | 0.03 | 18.75% |
| 2025-05-12 | 2025-03 | 0 | N/A | N/A | N/A |
| 2025-03-17 | 2024-12 | 0 | N/A | -0.03 | -21.43% |
| 2025-03-17 | 2024-12 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2025-07-15 | UBS | Upgrade | Buy | Buy |
| 2025-07-14 | Guggenheim | Upgrade | Buy | Buy |
| 2025-07-09 | Citigroup | Upgrade | Buy | Buy |
| 2025-06-30 | B of A Securities | Downgrade | Neutral | Underperform |
| 2024-09-30 | JP Morgan | Upgrade | Neutral | |
| 2024-09-10 | Guggenheim | Upgrade | Buy |
Profile
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-04-21 | CONTROL EMPRESARIAL DE CAPITALES, S.A. DE C.V. | Beneficial Owner of more than 10% of a Class of Security | 10.72M | Purchase |
| 2024-07-30 | GIROLAMO TODD C. J.D. | Officer | 163.86K | Conversion of Exercise of derivative security |
| 2025-06-02 | LEGORRETA PABLO G | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2023-11-16 | PALIHAPITIYA CHAMATH | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2025-02-03 | PEREIRA BRIAN J G | Director | 0.00 | Conversion of Exercise of derivative security |
| 2025-07-07 | WEBER DARIN J. | Officer | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-06-29 | Suvretta Capital Management, LLC | 12.34M | 33.57M | 9.14% |
| 2025-06-29 | Morgan Stanley | 5.99M | 16.29M | 4.44% |
| 2025-06-29 | Bleichroeder LP | 2.00M | 5.44M | 1.48% |
| 2025-06-29 | Blackrock Inc. | 1.76M | 4.80M | 1.31% |
| 2025-06-29 | JPMORGAN CHASE & CO | 1.67M | 4.54M | 1.24% |
| 2025-06-29 | Vanguard Group Inc | 1.57M | 4.26M | 1.16% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-06-29 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.38M | 3.74M | 1.02% |
| 2025-06-29 | Brighthouse Funds Trust I-Morgan Stanley Discovery Portfolio | 849.35K | 2.31M | 0.63% |
| 2025-06-29 | Morgan Stanley Insight Fund | 795.26K | 2.16M | 0.59% |
| 2025-06-29 | MORGAN STANLEY INSTITUTIONAL FUND TRUST-Discovery Portfolio | 733.31K | 1.99M | 0.54% |
| 2025-05-30 | VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 571.79K | 1.56M | 0.42% |
| 2025-07-30 | Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 492.01K | 1.34M | 0.36% |